Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan.

Neurology. 2000;55(9 Suppl 2):S8-14.
Links
Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan.
Goadsby PJ, Hargreaves RJ.
Institute of Neurology, London, UK.
Current theories on the etiology of migraine headache suggest that it is a neurovascular disorder (i.e., vascular change secondary to neural activation), with a primary CNS dysfunction giving rise to headache pain as a result of local intracranial vasodilatation and release of sensory neuropeptides from nerve endings in an activated trigeminal system. The serotonin 5-HT1B/1D agonists, known as the triptans, represent a major advance in the treatment of acute migraine. This article describes their mechanisms of action. The development of 5-HT1B/1D agonist drugs, such as rizatriptan, and the study of their pharmacology have enhanced our understanding of the mechanisms involved in the pathophysiology of migraine.
PMID: 11089513 [PubMed - indexed for MEDLINE]
Related articles
ReviewPathophysiology of migraine--new insights.
Can J Neurol Sci. 1999 Nov; 26 Suppl 3:S12-9.
[Can J Neurol Sci. 1999]
ReviewMechanisms of action of the 5-HT1B/1D receptor agonists.
Arch Neurol. 2002 Jul; 59(7):1084-8.
[Arch Neurol. 2002]
ReviewThe use of rizatriptan in the treatment of acute, multiple migraine attacks.
Neurology. 2000; 55(9 Suppl 2):S15-8.
[Neurology. 2000]
ReviewRizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.
Pharmacoeconomics. 2005; 23(12):1283-98.
[Pharmacoeconomics. 2005]
ReviewCurrent and emerging second-generation triptans in acute migraine therapy: a comparative review.
J Clin Pharmacol. 2000 Jul; 40(7):687-700.
[J Clin Pharmacol. 2000]
» See reviews... » See all...